Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Piperacillin v Carbenicillin in the Therapy for Serious Infections

Piperacillin v Carbenicillin in the Therapy for Serious Infections Abstract • One hundred seven patients were treated with either piperacillin (56) or carbenicillin (51) in an open randomized trial of hospitalized patients with pleuropulmonary (40), urinary tract (26), gynecologic (21), skin and soft-tissue (eight), joint (five), bone (three), and miscellaneous other infections (four). Patients with urinary tract infections were given 150 mg/ kg/day of piperacillin sodium or 200 mg/kg/day of carbenicillin sodium in divided doses every six hours intravenously. Patients with other infections were given 250 mg/kg/day of piperacillin sodium and 450 mg/kg/day of carbenicillin sodium; 53/56 (95%) patients treated with piperacillin and 45/51 (88%) patients treated with carbenicillin were cured clinically. In general, the drugs were well tolerated. There were, however, more adverse experiences in the group taking carbenicillin. Of special interest was the finding of liver function test abnormalities in 17/78 (21%) carbenicillin recipients (evaluative and nonevaluative cases). We concluded that piperacillin was effective and safe. It has potential for use in a great variety of infections. (Arch Intern Med 1982;142:2000-2005) References 1. Dickinson GM, Cleary TJ, Hoffman TA: Comparative evaluation of piperacillin in vitro. Antimicrob Agents Chemother 1978;14:919-921.Crossref 2. Winston DJ, Murphy W, Young LW, et al: Piperacillin therapy for serious bacterial infections. Am J Med 1980;69:255-261.Crossref 3. Thadepalli H, Rao B, White D, et al: Clinical evaluation of piperacillin. Chemotherapy 1980;26:377-383.Crossref 4. Prince AS, Neu HC: Uses of piperacillin, a semisynthetic penicillin, in the therapy of acute exacerbations of pulmonary disease in patients with cystic fibrosis. J Pediatr 1980;97:148-151. 5. Santos JI, Wenerstrom G, Saxon BJ, et al: Use of piperacillin in initial or supplanting therapy in serious bacterial infections , in Current Chemotherapy and Infectious Disease: Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1979, vol 1, pp 287-289. 6. Prince AS, Pancoast SJ, Neu HC: Efficacy of piperacillin in the therapy of serious infections , in Current Chemotherapy and Infectious Disease: Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1979, vol 1, pp 295-296. 7. Wittman DH, Teichmann W, Welter J, et al: Treatment of intraabdominal infections with piperacillin monotherapy. Read before the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Nov 4-6, 1981. 8. Lazaro EJ, Kaminski ZC, Seidel DR, et al: Comparative studies of parenteral piperacillin and cefoxitin in the management of surgical abdominal infections. Read before the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Nov 4-6, 1981. 9. Thadepalli H, Roy I, Bach VT, et al: In vitro activity of mezlocillin and its related compounds against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 1979;21:487-490.Crossref 10. Fu KP, Neu HC: Piperacillin: A new penicillin active against many bacteria resistant to other penicillins. Antimicrob Agents Chemother 1978;13:358-367.Crossref 11. Barry AL, Thornsberry C, Jones RN, et al: In vitro activity of mezlocillin and azlocillin compared with that of four other penicillins and two aminoglycosides. Cleve Clin Q 1980;47:311-319.Crossref 12. Monif GRG, Clark PR, Shuster JJ, et al: Susceptibility of the anaerobic bacteria, group D streptococci, Enterobacteriaceae, and Pseudomonas to semisynthetic penicillins: Carbenicillin, piperacillin, and ticarcillin. Antimocrob Agents Chemother 1978;14:643-649.Crossref 13. Wilson FM, Belamaric J, Lauter CB, et al: Anicteric carbenicillin hepatitis: Eight episodes in four patients. JAMA 1975;232:818-821.Crossref 14. Marier RL, Marinaccio AT, Sanders CV, et al: Susceptibility patterns of bacteria following therapy with piperacillin. J Antimicrob Chemother 1982;9( (suppl B) ):85-91.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Loading next page...
 
/lp/american-medical-association/piperacillin-v-carbenicillin-in-the-therapy-for-serious-infections-A06NplfXFH
Publisher
American Medical Association
Copyright
Copyright © 1982 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1982.00340240022005
Publisher site
See Article on Publisher Site

Abstract

Abstract • One hundred seven patients were treated with either piperacillin (56) or carbenicillin (51) in an open randomized trial of hospitalized patients with pleuropulmonary (40), urinary tract (26), gynecologic (21), skin and soft-tissue (eight), joint (five), bone (three), and miscellaneous other infections (four). Patients with urinary tract infections were given 150 mg/ kg/day of piperacillin sodium or 200 mg/kg/day of carbenicillin sodium in divided doses every six hours intravenously. Patients with other infections were given 250 mg/kg/day of piperacillin sodium and 450 mg/kg/day of carbenicillin sodium; 53/56 (95%) patients treated with piperacillin and 45/51 (88%) patients treated with carbenicillin were cured clinically. In general, the drugs were well tolerated. There were, however, more adverse experiences in the group taking carbenicillin. Of special interest was the finding of liver function test abnormalities in 17/78 (21%) carbenicillin recipients (evaluative and nonevaluative cases). We concluded that piperacillin was effective and safe. It has potential for use in a great variety of infections. (Arch Intern Med 1982;142:2000-2005) References 1. Dickinson GM, Cleary TJ, Hoffman TA: Comparative evaluation of piperacillin in vitro. Antimicrob Agents Chemother 1978;14:919-921.Crossref 2. Winston DJ, Murphy W, Young LW, et al: Piperacillin therapy for serious bacterial infections. Am J Med 1980;69:255-261.Crossref 3. Thadepalli H, Rao B, White D, et al: Clinical evaluation of piperacillin. Chemotherapy 1980;26:377-383.Crossref 4. Prince AS, Neu HC: Uses of piperacillin, a semisynthetic penicillin, in the therapy of acute exacerbations of pulmonary disease in patients with cystic fibrosis. J Pediatr 1980;97:148-151. 5. Santos JI, Wenerstrom G, Saxon BJ, et al: Use of piperacillin in initial or supplanting therapy in serious bacterial infections , in Current Chemotherapy and Infectious Disease: Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1979, vol 1, pp 287-289. 6. Prince AS, Pancoast SJ, Neu HC: Efficacy of piperacillin in the therapy of serious infections , in Current Chemotherapy and Infectious Disease: Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1979, vol 1, pp 295-296. 7. Wittman DH, Teichmann W, Welter J, et al: Treatment of intraabdominal infections with piperacillin monotherapy. Read before the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Nov 4-6, 1981. 8. Lazaro EJ, Kaminski ZC, Seidel DR, et al: Comparative studies of parenteral piperacillin and cefoxitin in the management of surgical abdominal infections. Read before the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Nov 4-6, 1981. 9. Thadepalli H, Roy I, Bach VT, et al: In vitro activity of mezlocillin and its related compounds against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 1979;21:487-490.Crossref 10. Fu KP, Neu HC: Piperacillin: A new penicillin active against many bacteria resistant to other penicillins. Antimicrob Agents Chemother 1978;13:358-367.Crossref 11. Barry AL, Thornsberry C, Jones RN, et al: In vitro activity of mezlocillin and azlocillin compared with that of four other penicillins and two aminoglycosides. Cleve Clin Q 1980;47:311-319.Crossref 12. Monif GRG, Clark PR, Shuster JJ, et al: Susceptibility of the anaerobic bacteria, group D streptococci, Enterobacteriaceae, and Pseudomonas to semisynthetic penicillins: Carbenicillin, piperacillin, and ticarcillin. Antimocrob Agents Chemother 1978;14:643-649.Crossref 13. Wilson FM, Belamaric J, Lauter CB, et al: Anicteric carbenicillin hepatitis: Eight episodes in four patients. JAMA 1975;232:818-821.Crossref 14. Marier RL, Marinaccio AT, Sanders CV, et al: Susceptibility patterns of bacteria following therapy with piperacillin. J Antimicrob Chemother 1982;9( (suppl B) ):85-91.Crossref

Journal

Archives of Internal MedicineAmerican Medical Association

Published: Oct 25, 1982

References